

1. A method for providing a retinal stimulator to a mammalian eye having an internal limiting membrane, the method comprising
- visualizing the internal limiting membrane of the eye,
- locating the retinal stimulator between the internal limiting membrane and the retina, and
- using the internal limiting membrane to secure the retinal stimulator.

5

0903259-041001

pat  
C17

2. The method of claim 1 wherein the retinal stimulator comprises a drug.
3. The method of claim 1 wherein the retinal stimulator comprises a device.
4. The method of claim 3 wherein the device is an array for electrostimulation of the retina.
5. The method of claim 4 wherein the device has external connectors.
6. The method of claim 1 wherein the substance is in a delivery vehicle.
7. The method of claim 6 wherein the delivery vehicle is selected from the group consisting of a capsule, a bead, a liposome, a sphere, a dissolvable biocompatible polymer sheet, and combinations thereof.
8. The method of claim 6 wherein the delivery vehicle provides slow-release drug delivery.

09632269-041001

SUB  
A2

9. A method for effecting treatment of a retina in a mammal comprising providing a therapeutic or preventive retinal stimulator between an internal limiting membrane and the retina to contact the retina and stimulate retinal cells to effect treatment.

092222550-04103  
T00140-092222550

11  
~~10.~~

The method of claim <sup>10</sup>~~9~~ wherein the treatment effected is for a condition selected from the group consisting of retinitis pigmentosa, macular degeneration, a degenerative retinal disease, and combinations thereof.

12  
~~11.~~

The method of claim <sup>10</sup>~~9~~ wherein the substance is a semiconductor microphotodiode array.

13  
~~12.~~

The method of claim <sup>10</sup>~~9~~ wherein the substance is an electrode array.

13.

The method of claim 9 wherein the substance is a vehicle containing a drug.

23  
~~14.~~

The method of claim <sup>22</sup>~~13~~ wherein the drug is selected from the group consisting of an  $\alpha$ -adrenergic agonist, a  $\beta$ -adrenergic agonist, an antiinflammatory agent, an antiproliferative agent, and combinations thereof.

15.

The method of claim 9 wherein the retinal cells stimulated are selected from the group consisting of photoreceptor cells, ganglion cells, neurofiber cells, and combinations thereof.

~~15~~  
~~16.~~

Sub C17

enhancing vision  
or injury com  
ernal limiting me  
retina to enhan

17.

17.

17

18.

10

19

9

20.

0

21.

21. The method of claim 16 wherein the patient has a retinal pathology selected from the group consisting of retinitis pigmentosa, macular degeneration, a retinal degenerative disease, and combinations thereof.

add

 $\frac{1}{A}$ 

**SECRET**